Posted on January 5, 2020 at 11:38 AM
Cannabidiol oil is classified as a Schedule I substance. There are currently several DEA-approved medical uses for cannabis. In fact, more than 85 percent of U.S. states have authorized the medical use of cannabis.
The DEA has classified cannabis as a Schedule I drug, meaning that the agency views it as having no medicinal value and low potential for abuse. The Schedule I classification means that DEA is prohibited from conducting research on cannabis and cannot include it in a list of drugs that may be prescribed to treat diseases Cannabidiol oil (CBD) has a wide variety of pharmacological effects. Although there have been many reports on CBD from the literature, there is still a paucity of research on its properties and interactions with the cannabinoid receptor system.
Despite the fact that hundreds of strains of Cannabis are cultivated around the world, the identity of the chemical compounds involved in marijuana psychoactivity remains largely unknown. The diverse presence of different phytocannabinoids and the unique set of molecular mechanisms mediating their effects on the brain complicate the identification of the main components of marijuana. CBD, the principal constituent of Cannabis, shows prominent biological activity in brain areas of the central nervous system and central nervous system depression disorders.
Cannabidiol oil has shown synergistic effects with marijuana in preclinical studies. That means CBD oil can be combined with tetrahydrocannabinol (THC), the psychoactive component of marijuana. These type of studies are also being done with THC-treated rats.
Some of the most interesting data has been produced in mice. The investigators found CBD and THC could produce synergistic effects on driving, which is important because some studies have shown that long-term driving impairment increases with chronic marijuana use. The dose-dependent effect of THC and CBD was surprising, because studies have shown THC has little to no effect on mice driving behavior.